168 related articles for article (PubMed ID: 34422248)
21. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies.
Prével C; Pellerano M; González-Vera JA; Henri P; Meunier L; Vollaire J; Josserand V; Morris MC
Biosens Bioelectron; 2016 Nov; 85():371-380. PubMed ID: 27203461
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis of Voltage-Dependent Anion Channel (VDAC1) as a Cancer Therapeutic Target or Diagnostic Biomarker.
Wang Z; Cheng Y; Song Z; Zhao R
Dis Markers; 2022; 2022():5946110. PubMed ID: 35958281
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
24. A novel variant in the 3' untranslated region of the CDK4 gene: interference with microRNA target sites and role in increased risk of cutaneous melanoma.
Pedace L; Cozzolino AM; Barboni L; De Bernardo C; Grammatico P; De Simone P; Buccini P; Ferrari A; Catricalà C; Colombo T; Donati P; Morrone A
Cancer Genet; 2014 Apr; 207(4):168-9. PubMed ID: 24797605
[No Abstract] [Full Text] [Related]
25. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
Georgantas RW; Streicher K; Luo X; Greenlees L; Zhu W; Liu Z; Brohawn P; Morehouse C; Higgs BW; Richman L; Jallal B; Yao Y; Ranade K
Pigment Cell Melanoma Res; 2014 Mar; 27(2):275-86. PubMed ID: 24289491
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
27. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
28. Identification of genes and pathways leading to metastasis and poor prognosis in melanoma.
Zhang X; Wang W; Wang Y; Jiang G
Aging (Albany NY); 2021 Sep; 13(18):22474-22489. PubMed ID: 34582363
[TBL] [Abstract][Full Text] [Related]
29. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.
Lang JM; Shennan M; Njauw JC; Luo S; Bishop JN; Harland M; Hayward NK; Tucker MA; Goldstein AM; Landi MT; Puig S; Gruis NA; Bergman W; Bianchi-Scarra G; Ghiorzo P; Hogg D; Tsao H
J Invest Dermatol; 2011 Feb; 131(2):480-6. PubMed ID: 21085193
[TBL] [Abstract][Full Text] [Related]
30. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.
Tormo D; Ferrer A; Gaffal E; Wenzel J; Basner-Tschakarjan E; Steitz J; Heukamp LC; Gütgemann I; Buettner R; Malumbres M; Barbacid M; Merlino G; Tüting T
Am J Pathol; 2006 Aug; 169(2):665-72. PubMed ID: 16877364
[TBL] [Abstract][Full Text] [Related]
31. A French CDK4-positive melanoma family with a co-inherited EDNRB mutation.
Soufir N; Ollivaud L; Bertrand G; Lacapère JJ; Descamps V; Vitoux D; Lebbe C; Wolkenstein P; Dupin N; Saiag P; Basset-Seguin N; Grandchamp B;
J Dermatol Sci; 2007 Apr; 46(1):61-4. PubMed ID: 17223014
[No Abstract] [Full Text] [Related]
32. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain.
Nagore E; Montoro A; Oltra S; Ledesma E; Botella-Estrada R; Millán JM; Oliver V; Fortea JM; Guillén C
Melanoma Res; 2005 Dec; 15(6):555-8. PubMed ID: 16314743
[No Abstract] [Full Text] [Related]
33. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
[TBL] [Abstract][Full Text] [Related]
34. Human sulfatase 1 exerts anti-tumor activity by inhibiting the AKT/ CDK4 signaling pathway in melanoma.
Lou X; Sun B; Song J; Wang Y; Jiang J; Xu Y; Ren Z; Su C
Oncotarget; 2016 Dec; 7(51):84486-84495. PubMed ID: 27806323
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
36. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
37. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma.
Nikolaou V; Kang X; Stratigos A; Gogas H; Latorre MC; Gabree M; Plaka M; Njauw CN; Kypreou K; Mirmigi I; Stefanaki I; Tsao H
Br J Dermatol; 2011 Dec; 165(6):1219-22. PubMed ID: 21801156
[TBL] [Abstract][Full Text] [Related]
38. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
39. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
40. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
